01.24.14
Zynex Inc., a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, neurological diagnosis and cardiac monitoring, has introduced its next-generation electrotherapy medical device, the TENSWave.
The TENSWave is a pain relief electrical stimulator that allows a treatment option based on the type of pain the patient is experiencing, and contains the same ease of use features as the company's NexWave device. The NexWave is a multiple-mode stimulator which allows users a choice of treatment options. This device incorporates Interferential Current (IFC), Transcutaneous Electrical Nerve Stimulation (TENS), and Neuromuscular ElectricalStimulation.
"We are very excited about the introduction of this new product into our existing electrotherapy sales channel," Zynex CEO Thomas Sandgaard said. "We believe this new product will provide our sales force an additional tool to fuel revenue growth."
Founded in 1996, Zynex operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex NeuroDiagnostics sells the company's proprietary NeuroMove device, which is designed to help stroke and spinal cord injury patients and currently is expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, was established to develop and market medical devices for non-invasive cardiac monitoring.
The TENSWave is a pain relief electrical stimulator that allows a treatment option based on the type of pain the patient is experiencing, and contains the same ease of use features as the company's NexWave device. The NexWave is a multiple-mode stimulator which allows users a choice of treatment options. This device incorporates Interferential Current (IFC), Transcutaneous Electrical Nerve Stimulation (TENS), and Neuromuscular ElectricalStimulation.
"We are very excited about the introduction of this new product into our existing electrotherapy sales channel," Zynex CEO Thomas Sandgaard said. "We believe this new product will provide our sales force an additional tool to fuel revenue growth."
Founded in 1996, Zynex operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex NeuroDiagnostics sells the company's proprietary NeuroMove device, which is designed to help stroke and spinal cord injury patients and currently is expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, was established to develop and market medical devices for non-invasive cardiac monitoring.